CEVENFACTA

This brand name is authorized in Austria, France, Italy, Lithuania, United Kingdom

Active ingredients

The drug CEVENFACTA contains one active pharmaceutical ingredient (API):

1 Eptacog beta (activated)
UNII AC71R787OV - COAGULATION FACTOR VIIA RECOMBINANT HUMAN

Pharmacological doses of rFVIIa activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.

Read about Coagulation factor VIIa

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
CEVENFACTA Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
B02BD08 Eptacog alfa (activated) B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: FR Base de données publique des médicaments Identifier(s): 67797496, 68117241, 68677884
Country: IT Agenzia del Farmaco Identifier(s): 050298013, 050298025, 050298037
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1095406, 1095407, 1095408

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.